Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Contraception

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,862 result(s) found for: Contraception. Displaying page 330 of 544.
    «« First « Previous 326  327  328  329  330  331  332  333  334  Next» Last»»
    EudraCT Number: 2007-003054-28 Sponsor Protocol Number: P070104 Start Date*: 2007-10-17
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude des marqueurs biologiques, histologiques et d’imagerie dans le traitement de 1ère ligne du carcinome à cellules claires du rein en situation métastatique par Sunitinib avant et après néphrec...
    Medical condition: Carcinome à cellules claires du rein en situation métastatique.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009251 carcinome à cellules claires du rein métastasé PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022329-13 Sponsor Protocol Number: 4791 Start Date*: 2010-10-26
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: Etude de phase I associant la rapamycine et l’irinotecan dans toutes tumeurs solides réfractaires de l’enfant
    Medical condition: Tumeurs solides réfractaires de l'enfant
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000320-40 Sponsor Protocol Number: SLx-2101-07-05 Start Date*: 2007-06-14
    Sponsor Name:Surface Logix, Inc.
    Full Title: A pilot Phase IIa randomised, double blind, placebo-controlled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5,...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019935-37 Sponsor Protocol Number: ML25346 Start Date*: 2010-09-15
    Sponsor Name:Roche Oy
    Full Title: A pragmatic, randomized, parallel group study of the effect on disease remission, work productivity, and tolerability of tocilizumab in combination with DMARDs and individually designed best practi...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-001069-32 Sponsor Protocol Number: D1449L0001 Start Date*: Information not available in EudraCT
    Sponsor Name:Psychosis Early Detection and Intervention Centre, Department for Psychiatry, UKE Hamburg
    Full Title: A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years
    Medical condition: A prospective 8 weeks acute phase study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020341-27 Sponsor Protocol Number: GFM-Aza intensif Start Date*: 2010-06-22
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients
    Medical condition: Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024479-20 Sponsor Protocol Number: E5501-G000-203 Start Date*: 2011-11-24
    Sponsor Name:Eisai Limited
    Full Title: A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, with an Open-Label Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects ...
    Medical condition: Thrombocytopenia associated with chronic hepatitis C virus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    16.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    16.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    16.1 10005329 - Blood and lymphatic system disorders 10039884 Secondary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-010083-42 Sponsor Protocol Number: 6462 Start Date*: 2009-06-29
    Sponsor Name:Barts Health NHS Trust
    Full Title: RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VITAMIN D SUPPLEMENTATION IN ADULT AND ADOLESCENT PATIENTS WITH ASTHMA
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002581-35 Sponsor Protocol Number: CL-033-II-02 Start Date*: 2007-09-25
    Sponsor Name:IDEA AG
    Full Title: Multiple dose, double-blind, double-dummy, placebo and active controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for the treatment of muscle soreness from exercise
    Medical condition: The study population is a healthy population who are voluntarily participating in this clinical trial. This study will compare the PK profile after e.c. and oral application of the same dosage of ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028332 Muscle soreness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004640-21 Sponsor Protocol Number: CT327-2003 Start Date*: 2012-02-13
    Sponsor Name:Creabilis Limited
    Full Title: A Randomized, Placebo-controlled Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w topical CT327 when Applied Twice Daily in Subjects with Psoriasis Vulg...
    Medical condition: Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000879-14 Sponsor Protocol Number: CT/11.01 Start Date*: 2011-06-06
    Sponsor Name:Hellenic Oncology Research Group (H.O.R.G.)
    Full Title: A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC).
    Medical condition: Relapsed and Refractory Small Cell Lung Cancer
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018334-51 Sponsor Protocol Number: POX-MVA-032 Start Date*: 2010-07-15
    Sponsor Name:Bavarian Nordic A/S
    Full Title: An open-label, non-controlled study to immunize healthy volunteers actively working with or in the vicinity of replicating Vaccinia virus with IMVAMUNE® (MVA-BN®)
    Medical condition: Healthy subjects actively working with or in the vicinity of replicating Vaccinia virus will receive immunization IMVAMUNE to offer protection against accidential Vaccinia virus infection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10041197 Smallpox PT
    12.1 10066048 Vaccinia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002378-30 Sponsor Protocol Number: CPN710102 Start Date*: 2012-08-23
    Sponsor Name:CellAct Pharma GmbH
    Full Title: Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma
    Medical condition: Treatment of Therapy refractory none small cell lung Cancer (NSCLC), small cell lung Cancer (SCLC) and Biliary carcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019121-34 Sponsor Protocol Number: E-3810-I-01 Start Date*: 2011-03-28
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics, and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase ...
    Medical condition: Dose escalation: solid tumors failing standard therapy. Dose-expansion: solid tumors A) with FGFR1 amplification and for breast cancer ? 1 prior endocrine therapy if ER+ or ? 1 chemotherapy otherwi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-013422-17 Sponsor Protocol Number: CHUBX2009/09 Start Date*: 2009-12-29
    Sponsor Name:CHU de Bordeaux
    Full Title: Etude de l’efficacité et de la toxicité d’une stratégie d’allogreffe de cellules souches hématopoïétiques à conditionnement atténué dans le lymphome folliculaire en rechute chimiosensible.
    Medical condition: Follicular lymphoma Allogeneic hematopoietic stem cell transplantation Reduced-intensity conditioning
    Disease: Version SOC Term Classification Code Term Level
    12.0 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024000-10 Sponsor Protocol Number: 101MS206 Start Date*: 2011-06-28
    Sponsor Name:Biogen Idec Limited
    Full Title: A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005169-78 Sponsor Protocol Number: P080301 Start Date*: 2009-02-23
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Traitement des récidives de glioblastomes par le SUTENT (SU11248) : essai de phase 2 avec étude translationnelle biologique et en imagerie
    Medical condition: Patients atteints de glioblastomes en récidive
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018336 Glioblastomes PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019369-27 Sponsor Protocol Number: ANX001-01 Start Date*: 2010-07-23
    Sponsor Name:Anxiofit Ltd.
    Full Title: A Phase II randomized, double-blind, parallel-group, multi-site, placebo controlled fixed-dose study of Echinaceae angustifoliae root dry extract in 24 outpatients with generalized anxiety disorder...
    Medical condition: Generalized Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018075 Generalised anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004847-61 Sponsor Protocol Number: 008717QM Start Date*: 2013-01-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhan...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002348-28 Sponsor Protocol Number: 0462-083 Start Date*: 2011-06-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Single-Dose Pharmacokinetics of MK-0462 in Migraineurs Aged 6 to 17 Years
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 326  327  328  329  330  331  332  333  334  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 12:39:50 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA